These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents. Cannon CP Am Heart J; 2000 Dec; 140(6 Suppl):S154-60. PubMed ID: 11100010 [TBL] [Abstract][Full Text] [Related]
4. Thrombolytic therapy in Europe: current status. Vahanian A Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000 [TBL] [Abstract][Full Text] [Related]
5. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. Mehta RH; Alexander JH; Van de Werf F; Armstrong PW; Pieper KS; Garg J; Califf RM; Granger CB JAMA; 2005 Apr; 293(14):1746-50. PubMed ID: 15827313 [TBL] [Abstract][Full Text] [Related]
6. Patency trials with reteplase (r-PA): what do they tell us? Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406 [TBL] [Abstract][Full Text] [Related]
7. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073 [TBL] [Abstract][Full Text] [Related]
8. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB; Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088 [TBL] [Abstract][Full Text] [Related]
11. [t-PA in thrombolytic therapy of acute myocardial infarct]. Rutsch W; Schmutzler H Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690 [TBL] [Abstract][Full Text] [Related]
12. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780 [TBL] [Abstract][Full Text] [Related]
13. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. Aylward PE; Wilcox RG; Horgan JH; White HD; Granger CB; Califf RM; Topol EJ Ann Intern Med; 1996 Dec; 125(11):891-900. PubMed ID: 8967669 [TBL] [Abstract][Full Text] [Related]
14. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO. Bates ER Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479 [TBL] [Abstract][Full Text] [Related]